Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study.
Jay VisariaNeeraj N IyerAmit D RavalSheldon X KongTodd HobbsJonathan BouchardDavid M KernVincent J WilleyPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
Vascular disease increased the cost burden for individuals with T2DM. The cost impact of diabetes and vascular disease was highest in the year after diagnosis, and persisted for at least seven additional years, while the cost of T2DM patients without vascular disease trended lower than for matched non-DM patients. These data highlight potential costs that could be offset by earlier and more effective detection and management of T2DM aimed at reducing vascular disease burden.
Keyphrases
- end stage renal disease
- glycemic control
- healthcare
- cardiovascular disease
- type diabetes
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- machine learning
- risk factors
- patient reported outcomes
- skeletal muscle
- risk assessment
- electronic health record
- climate change
- human health
- health information